Abbott reported Diagnostics sales of $1.12 billion, up 2 percent on a reported basis and 7 percent excluding foreign currency effects.
The companion test will let doctors identify the best treatment for CLL patients with 17p deletions, a subset that has historically lacked therapeutic options.
The test, which was previously approved for CLL prognosis, is now cleared for use in identifying patients who may benefit from AbbVie and Genentech's Venclexta.
Abbott Molecular has been building a PCR-based system from the ground up and plans to sell it in parallel with the m2000, eventually replacing that system.
The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.
The company notified the Securities and Exchange Commission of the subpoena and noted that it will delay filing its annual earnings for 2015.
Abbott's move came as somewhat of a surprise, but analysts have noted the potential for a trend in point-of-care diagnostics acquisitions.
Alere will become an Abbott subsidiary, and Alere shareholders will receive $56 per common share in cash at the completion of the transaction.
The company reported $1.22 billion in Q4 Worldwide Diagnostics sales, including $126 million in molecular diagnostics sales due to growth in infectious disease testing.
Executives from 23andMe, Myriad Genetics, Genomic Health, and Alere provided updates on their companies at the JP Morgan Healthcare Conference in San Francisco.
In PLOS this week: preconception carrier screening program results, comparative genomics-based analysis of Elizabethkingia meningoseptica, and more.
Canadian regulators are beginning to share information from new drug studies, Undark reports.
In a column at the Dallas Morning News, the Stanley Medical Research Institute's E. Fuller Torrey says the Human Genome Project hasn't delivered on promised results.
Researchers explore a possible genetic cause for some cases of sudden infant death syndrome, KOMO News reports.